<- Go home

Added to YB: 2026-05-01

Pitch date: 2026-04-30

PSNL [bullish]

Personalis, Inc.

+76.71%

current return

Author Info

No bio for this author

Company Info

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.

Market Cap

$1.2B

Pitch Price

$5.54

Price Target

N/A

Dividend

N/A

EV/EBITDA

-11.61

P/E

-11.01

EV/Sales

15.26

Sector

Life Sciences Tools and Services

Category

growth

Show full summary:
Pitch Time: $PSNL

PSNL: Cancer detection test w/ higher sensitivity than $NTRA. Secured reimbursement for breast & lung (IO pending). Margins to expand from 11% to 60%+ as reimbursement pricing kicks in. Clinical volumes to 3x in 2026 via $TEM partnership (owns 20%). 35% net margin potential at scale. Cash burn to decline as margins improve.

Read full article (2 min)